Physician profile
Steven Heath
NPI 1366497166
$6,357.86
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $936 · 2021: $1,642 · 2022: $1,900 · 2023: $257 · 2024: $57.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $313.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $756.73 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.98 | 2019-2023 | Jardiance, Synjardy |
| Amgen INC. | $402.22 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $356.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $338.75 | 2019-2022 | |
| Pfizer INC. | $333.73 | 2019-2021 | |
| Novo Nordisk INC | $324.03 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $297.55 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $208.22 | 2020-2021 | |
| Gilead Sciences, INC. | $191.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $190.91 | 2019-2023 | |
| Lilly USA, LLC | $189.24 | 2019-2022 | |
| Amarin Pharma, INC. | $183.30 | 2019-2022 | |
| Astellas Pharma US INC | $175.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.69 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Heath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.